Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK11 | Q15759 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
| ▸ | AOC2 | O75106 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1995821 | 0.87 | MAOB (0.59) | CHRNA7HDAC3HDAC1CYP2A6MAOB | |
| SCHEMBL30547775 | 0.87 | MAOB (0.59) | CHRNA7HDAC3HDAC1CYP2A6MAOB | |
| SCHEMBL30317473 | 0.85 | MAPK11 (0.53) | MAPK11MAPK14CHRNA7HDAC3HDAC1 | |
| SCHEMBL27396095 | 0.82 | MAPK11 (0.48) | MAPK11MAPK14CHRNA7HDAC3HDAC1 | |
| SCHEMBL4102767 | 0.81 | AR (0.53) | MAPK11MAPK14CHRNA7HDAC3HDAC1 | |
| SCHEMBL233310 | 0.81 | HDAC11 (0.50) | HDAC3HDAC1HDAC4HDAC7HDAC2 | |
| Hydrochloric Acid SCHEMBL27535363 | 0.81 | MAPK11 (0.47) | MAPK11MAPK14CHRNA7HDAC3HDAC1 | |
| SCHEMBL231079 | 0.80 | MAPK11 (0.55) | MAPK11MAPK14HDAC3HDAC1HDAC4 | |
| SCHEMBL30308312 | 0.80 | CYP2A6 (0.51) | MAPK11MAPK14CHRNA7HDAC3HDAC1 | |
| SCHEMBL233322 | 0.80 | CYP2A6 (0.51) | MAPK11MAPK14CHRNA7HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778928-B2 | Indolyl-oxadiazolyl-diazabicyclononane derivatives and their medical and diagnostical use | DANPET AB (SE) | 2014-07-15 | — | — | US | disclosed |
| US-20120003153-A1 | NOVEL INDOLYL-OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL AND DIAGNOSTICAL USE | NEUROSEARCH A/S (DK) | 2012-01-05 | — | — | US | disclosed |
| CN-102300574-A | Novel indolyl-oxadiazolyl-diazabicyclononane derivatives and their medical and diagnostical use | — | 2011-12-28 | — | — | CN | disclosed |
| WO-2009071577-A1 | OXADIAZOLE DERIVATIVES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071577-A1 | OXADIAZOLE DERIVATIVES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003153-A1 | NOVEL INDOLYL-OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL AND DIAGNOSTICAL USE | CHRNA6, CHRNA10, CHRNA3 | MAPK11 1267/4885MAPK14 1464/4885CHRNA7 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.